Monday, May 11, 2026 9:17:34 AM
ANIP
I don't own ANIP at this point, but have owned it before, and for disclosures purposes I would think about buying it back in the low to mid 70's if it ever got there. But I wasn't surprised that it didn't go up in fact looking at the quarter I thought it would trade into the 70's short-term.
Keep In mind the midpoint was raised about .35 this year. Having said that this upfront payment and milestone payments are one time or at least episodic in nature. Hence I would ex this out. I don't believe they were in guidance before, hence they actually lowered guidance on the rest of the year, hence why the stock is down. I mean based on my math 35 million, taxing that at say 25%, they have lowered the mid point for the year if you ex this episodic revenue and earnings by .87. Now do I believe they are being conservative and they see it as a way to continue to raise guidance in future quarters, most likely that is the case. having said that based on the math, I understand why the stock sold off a little, because although it looks like they raised guidance in the short-term in reality if you don't like to add in this episodic revs and earnings which appear to have not been built into guidance originally, at least that is my take, they really lower the bar almost by 10% this year which isn't great in my opinion. Now I do believe that probably this company is being conservative, and I do believe the future is bright here, so there is that as well. Having said that I can't say this quarter's guide was a positive it was a slight negative in my opinion. All is just my opinion and I could always be wrong though.
I don't own ANIP at this point, but have owned it before, and for disclosures purposes I would think about buying it back in the low to mid 70's if it ever got there. But I wasn't surprised that it didn't go up in fact looking at the quarter I thought it would trade into the 70's short-term.
Keep In mind the midpoint was raised about .35 this year. Having said that this upfront payment and milestone payments are one time or at least episodic in nature. Hence I would ex this out. I don't believe they were in guidance before, hence they actually lowered guidance on the rest of the year, hence why the stock is down. I mean based on my math 35 million, taxing that at say 25%, they have lowered the mid point for the year if you ex this episodic revenue and earnings by .87. Now do I believe they are being conservative and they see it as a way to continue to raise guidance in future quarters, most likely that is the case. having said that based on the math, I understand why the stock sold off a little, because although it looks like they raised guidance in the short-term in reality if you don't like to add in this episodic revs and earnings which appear to have not been built into guidance originally, at least that is my take, they really lower the bar almost by 10% this year which isn't great in my opinion. Now I do believe that probably this company is being conservative, and I do believe the future is bright here, so there is that as well. Having said that I can't say this quarter's guide was a positive it was a slight negative in my opinion. All is just my opinion and I could always be wrong though.
---All above is just my humble opinion.
And I could always be wrong.
And as always do your own DD.---
http://www.investorshub.com/boards/board.asp?board_id=5316
Recent ANIP News
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/27/2026 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 08:13:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:16:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:15:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:15:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2026 03:04:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 12:27:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 10:34:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:51:01 PM
- ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook • IH Market News • 05/08/2026 01:45:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 10:58:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 10:56:34 AM
- ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance • GlobeNewswire Inc. • 05/08/2026 10:50:00 AM
- ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET • GlobeNewswire Inc. • 04/24/2026 10:50:00 AM
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity • GlobeNewswire Inc. • 04/20/2026 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:40:36 PM
- ANI Pharmaceuticals rolls out generic carbamazepine extended-release capsules • IH Market News • 04/13/2026 03:12:39 PM
- ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules • GlobeNewswire Inc. • 04/13/2026 10:50:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/09/2026 08:14:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/09/2026 08:13:29 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:12:05 PM
- ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet • GlobeNewswire Inc. • 04/08/2026 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:21:22 PM
- ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology • GlobeNewswire Inc. • 04/07/2026 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 09:28:48 PM
